HF  Deerfield Management Company, L.P.

https://www.deerfield.com





     Office Locations:

780 Third Avenue, 37th Floor
New York, NY 10017
Phone: 212-551-1600
Fax: 212-599-3075

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Growth


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Deerfield Management Company, L.P. is an employee owned hedge fund sponsor. The firm manages funds in excess of $7 billion. A portion of all profits from the Deerfield funds are donated to the Deerfield Foundation, including all profits from selected funds. It invests in public and private equity markets of the United States. The firm makes its private equity investments in large cap and growth companies. It typically invests in healthcare sector which includes pharmaceuticals, biotechnology, generic drugs, over the counter drugs, medical devices, medical equipment, diagnostics, hospital supplies, hospital services, acute care hospitals, nursing homes, psychiatric hospitals, alternate site providers, home care, physician practice management, medical software HMOs, health insurers, benefit management companies, distributors, drug stores, and animal healthcare products and services


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Howie Furst M.D. Partner
    James E. Flynn Managing Partner
    Karen Heidelberger Chief Partnership and Communications Officer
    Paul Takats Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      06/08/2018


      Metacrine


      CA


      $65,000,000


      Series C


      05/24/2018


      Strata Oncology


      MI


      $26,000,000


      Series B


      05/21/2018


      FogPharma


      MA


      $66,000,000


      Series B


      04/09/2018


      Constellation Pharmaceuticals


      MA


      $100,000,000


      


      04/04/2018


      Arvinas


      CT


      $55,000,000


      Series C


      03/23/2018


      Dracen Pharmaceuticals


      MD


      $40,000,000


      Series A


      03/20/2018


      Pairwise Plants


      CA


      $25,000,000


      Series A


      02/27/2018


      Generation Bio


      MA


      $100,000,000


      Series B


      01/11/2018


      Braeburn Pharmaceuticals


      NJ


      $110,000,000


      Mezzanine


      01/05/2018


      Quartet Health


      NY


      $40,000,000


      Series C


      11/30/2017


      Fractyl Labs


      MA


      $44,000,000


      Series D


      10/18/2017


      Blade Therapeutics


      CA


      $45,000,000


      Series B


      08/01/2017


      Homology Medicines


      MA


      $83,500,000


      Series B


     

    Portfolio companies include:

     

    Recent News: